top of page
Browse by category
Search


Mortality rates linked to obesity-related heart disease increase especially among men
The rate of deaths from ischemic heart disease related to obesity nearly tripled in the US over a two-decade span, according to research...


Surgical staplers market to reach US$7.29 billion by 2029
The global surgical staplers market is projected to reach US$7.29 Billion by 2029 from US$5.15 billion in 2024 at a compound annual...


Journal watch 27/11/2024
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...


Liraglutide after RYGB results in significant weight loss and resolution of obesity-related conditions
Adjunctive use of liraglutide at a dose of 3mg/day with conversional Roux-en-Y Gastric Bypass (cRYGB) results in significant weight loss,...


Discovery of Neuropeptide Y could lead to simpler and cheaper drugs to control obesity and weight gain
An international team of researchers has discovered a new component of the peripheral nervous system that acts by increasing energy...


Study examines California's legislative efforts on obesity and finds critical insights into policy trends and success rates over two decades
A recent multi-campus study, co-led by public health researchers from University of California (UC) Irvine and UC Merced, is the first of...


Allurion launches AllurionMeds first AI-native compounded GLP-1 program
Allurion Technologies has launched AllurionMeds, a unique offering to patients that combines affordable and accessible weight loss...


COMBINE trial: Glucose clamp technique as part of a new type 2 diabetes research trial
Researchers at Leicester Diabetes Centre (LDC) have successfully started using the glucose clamp technique as part of a new type 2...


Laekna and Eli Lilly to develop ActRIIA antibody for muscle-preserving weight loss in obesity
Laekna Therapeutics has entered a clinical collaboration with Eli Lilly to accelerate the development of LAE102, a novel Activin Receptor...


More than half of US adults could benefit from GLP-1 medications
More than half of US adults, an estimated that 137 million people, are eligible for semagludtide for weight loss, diabetes management, or...
Browse by tag






bottom of page
